Core Insights - Blueprint Medicines Corporation has showcased its leadership in advancing care for patients with systemic mastocytosis (SM) through data presentations at major congresses, emphasizing the effectiveness of AYVAKIT®/AYVAKYT® (avapritinib) as a standard treatment for both indolent and advanced forms of SM [1][2][9]. Data Presentation Highlights - The presentations included large patient populations from the PIONEER, PATHFINDER, and EXPLORER trials, demonstrating long-term benefits of AYVAKIT with follow-up periods of up to five years for indolent systemic mastocytosis (ISM) and 6.5 years for advanced SM [2][5]. - AYVAKIT has shown transformative clinical outcomes, including sustained disease control in ISM and prolonged survival in advanced SM, leading to an expanded view among clinicians regarding appropriate candidates for disease-modifying therapy [2][7]. Clinical Efficacy and Safety - AYVAKIT demonstrated robust improvements in overall symptoms and quality of life measures over 144 weeks, with a low treatment-related adverse event discontinuation rate of 3% and common adverse events including low-grade edemas, headache, and nausea [7][23]. - The Revised Mutation-Adjusted Risk Score (MARS-R) tool was validated for assessing overall survival risks in advanced SM patients treated with AYVAKIT, showing meaningful survival benefits across all prognostic categories [7][12]. Disease Burden and Patient Impact - The PRISM study highlighted the substantial disease burden faced by patients with ISM, including physical, social, and emotional challenges that significantly disrupt daily life [6][12]. - Patients reported various disease-related impacts, such as limitations in physical activities and work, as well as issues with pain, anxiety, and adjustments in daily routines to avoid triggers [8][12]. Regulatory and Market Position - AYVAKIT is the first and only FDA-approved treatment targeting the root cause of SM, with approvals for both advanced SM and ISM, and is marketed in 16 countries globally [14][26]. - The company aims to expand its impact by advancing a broad pipeline of programs in mast cell diseases and solid tumors, leveraging its established research and commercial capabilities [26].

SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP has launched an investigation into whether the board members of Blueprint Medicines Corporation (NASDAQ: BPMC) breached their fiduciary duties in connection with the proposed sale of the Company to Sanofi (NASDAQ: SNY). On June 2, 2025, Blueprint Medicines announced the execution of a definitive agreement with Sanofi for the acquisition of all outstanding shares of Blueprint Medicines for $129.00 per share in cash. Whereas shareholders also ...

Blueprint Medicines (BPMC) 2025 Conference May 07, 2025 12:00 PM ET Speaker0 Pleasure to welcome the next presenting company, Blueprint Medicines. Joining us here on stage is CEO, Kate Havlund, as well as Fuad Nimani, president and president of research and development. Thank you both for for being here. For all of you in the audience and those in the webcast, you know, this is this has been one of our top picks from soup to nuts, the company that developed drugs, got it to commercialization, and now is on ...

Blueprint Medicines Corporation (BPMC) reported first-quarter 2025 adjusted loss of 74 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 42 cents. The adjusted figure excludes the one-time equity investment gain of $50 million recorded in the reported quarter, following the closing of GSK's acquisition of IDRx. The company incurred a loss of $1.32 per share in the year-ago quarter.Quarterly revenues of $149.4 million, generated entirely from the net product sales of Ayvakit, mi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________ FORM 10-Q (Mark One) For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 _____________________________ BLUEPRINT MEDICINES CORPORATION ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact Name of Registrant as Specified in Its Ch ...

Blueprint Medicines (BPMC) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $1.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -76.19%. A quarter ago, it was expected that this cancer drug developer would post a loss of $0.70 per share when it actually produced a loss of $0.79, delivering a surprise of -12.86%.Over the last four quarters, the ...

Blueprint Medicines (BPMC) Q1 2025 Earnings Call May 01, 2025 08:00 AM ET Company Participants Jenna Cohen - Vice President of Investor Relations and Global Business CommunicationsKate Haviland - President & CEOPhilina Lee - Chief Commercial OfficerBecker Hewes - Chief Medical OfficerMike Landsittel - Chief Financial OfficerLaura Prendergast - Vice PresidentChristina Rossi - Chief Operating OfficerPaul Jeng - Vice PresidentMichael Yee - Managing DirectorMark Aleynick - Biotechnology Equity ResearchReni Benj ...

Blueprint Medicines Driving growth and innovation with operational excellence First quarter 2025 financial and operating results INTRODUCTION AYVAKIT PERFORMANCE Kate Haviland Chief Executive Officer Philina Lee, PhD Chief Commercial Officer PROGRESS May 1, 2025 First quarter 2025 financial and operating results Becker Hewes, MD Chief Medical Officer FINANCIAL RESULTS Mike Landsittel Chief Financial Officer 2 CLINICAL Forward-looking statements This presentation contains forward-looking statements within th ...

Blueprint Medicines (BPMC) Q1 2025 Earnings Call May 01, 2025 08:00 AM ET Speaker0 Good morning. My name is Angela Lang, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines' First Q twenty twenty five Earnings Release and Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer Thank you. Jenna Cohen, you may begin your conference. Speaker1 Thank you, ...

Blueprint Medicines (BPMC) Q1 2025 Earnings Call May 01, 2025 08:00 AM ET Company Participants Jenna Cohen - Vice President of Investor Relations and Global Business CommunicationsKate Haviland - President & CEOPhilina Lee - Chief Commercial OfficerBecker Hewes - Chief Medical OfficerMike Landsittel - Chief Financial OfficerLaura Prendergast - Vice PresidentChristina Rossi - Chief Operating OfficerPaul Jeng - Vice PresidentMichael Yee - Managing DirectorMark Aleynick - Biotechnology Equity ResearchReni Benj ...